Equities Analysts Set Expectations for CLDX FY2025 Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Leerink Partnrs cut their FY2025 earnings per share (EPS) estimates for Celldex Therapeutics in a report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now expects that the biopharmaceutical company will post earnings of ($3.26) per share for the year, down from their previous estimate of ($3.22). The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share. Leerink Partnrs also issued estimates for Celldex Therapeutics’ FY2026 earnings at ($4.45) EPS and FY2027 earnings at ($4.20) EPS.

CLDX has been the subject of several other reports. Cantor Fitzgerald reissued an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, January 29th. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research report on Thursday, December 19th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Stock Performance

CLDX stock opened at $23.29 on Friday. Celldex Therapeutics has a 52-week low of $22.17 and a 52-week high of $53.18. The stock’s 50 day moving average is $25.32 and its two-hundred day moving average is $30.67.

Insider Activity at Celldex Therapeutics

In related news, CEO Anthony S. Marucci bought 11,500 shares of Celldex Therapeutics stock in a transaction dated Monday, November 11th. The stock was acquired at an average cost of $26.82 per share, with a total value of $308,430.00. Following the completion of the acquisition, the chief executive officer now directly owns 40,284 shares in the company, valued at approximately $1,080,416.88. This trade represents a 39.95 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 3.80% of the company’s stock.

Institutional Trading of Celldex Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. KBC Group NV increased its position in shares of Celldex Therapeutics by 31.2% in the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 495 shares in the last quarter. E Fund Management Co. Ltd. acquired a new position in Celldex Therapeutics in the 4th quarter worth approximately $273,000. AQR Capital Management LLC grew its position in Celldex Therapeutics by 23.7% during the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock worth $291,000 after purchasing an additional 1,504 shares in the last quarter. Los Angeles Capital Management LLC raised its stake in Celldex Therapeutics by 128.9% during the 4th quarter. Los Angeles Capital Management LLC now owns 15,421 shares of the biopharmaceutical company’s stock valued at $390,000 after purchasing an additional 8,683 shares during the period. Finally, Handelsbanken Fonder AB lifted its holdings in shares of Celldex Therapeutics by 23.2% in the third quarter. Handelsbanken Fonder AB now owns 13,800 shares of the biopharmaceutical company’s stock valued at $469,000 after purchasing an additional 2,600 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.